Back to top
more

Atara Biotherapeutics (ATRA)

(Delayed Data from NSDQ)

$11.32 USD

11.32
14,045

-0.23 (-1.99%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $11.33 +0.01 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of 0% and 10.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -15.38% and 90.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus

by Zacks Equity Research

ABT's Structural Heart, Rhythm Management and Neuromodulation businesses are likely to have driven its first-quarter 2025 performance.

Zacks Equity Research

Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 68.85% and 150.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of 0.68% and 1,467.86%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arcellx (ACLX) delivered earnings and revenue surprises of -38.10% and 44.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Geron (GERN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Geron (GERN) delivered earnings and revenue surprises of -100% and 4.67%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 33% upside potential for Atara Biotherapeutics (ATRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate

by Zacks Equity Research

Atara stock plunges 41% upon the FDA issuance of a CRL against its BLA for Ebvallo to treat EBV+ PTLD. The company is also facing a severe cash crunch.

Zacks Equity Research

Has Incyte (INCY) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Incyte (INCY) and Atara Biotherapeutics (ATRA) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why You Should Consider Buying Atara Biotherapeutics Stock

by Zacks Equity Research

Here, we discuss some reasons why buying ATRA stock now may turn out to be a prudent move.

Zacks Equity Research

Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why

by Zacks Equity Research

Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 22.28% and 74.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 26.67% and 14.41%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -3.54% and 4%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -148% and 40.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 33.33% and 3.87%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Apyx Medical (APYX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Apyx (APYX) delivered earnings and revenue surprises of -5.56% and 4.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clene (CLNN) delivered earnings and revenue surprises of 33.75% and 9%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy

by Zacks Equity Research

Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline

by Zacks Equity Research

Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.

Zacks Equity Research

GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals

by Zacks Equity Research

GSK's depemokimab has the potential to become the first ultra-long-acting biologic for severe asthma with a six-month dosing schedule

Zacks Equity Research

Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 37.84% and 1.32%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?